Literature DB >> 19332096

Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.

Vassilis Samaras1, Christina Piperi, Georgia Levidou, Athanasios Zisakis, Nikolaos Kavantzas, Marios S Themistocleous, Efstathios I Boviatsis, Calypso Barbatis, Robert W Lea, Anastasios Kalofoutis, Penelope Korkolopoulou.   

Abstract

Malignant astrocytomas are highly vascular neoplasms with potent angiogenic activity. The present study aimed to investigate peripheral and local expression of interleukin (IL)-8 in astrocytomas with possible associations to IL-6, cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) expression, and microvessel morphometry. IL-6- and IL-8-secreting peripheral blood monocytes (PBMCs) were evaluated in 17 glioblastoma (WHO grade IV), 5 anaplastic astrocytoma (WHO grade III), and 6 diffuse astrocytoma patients (WHO grade II), in parallel with 23 healthy controls using enzyme-linked immunosorbent spot (ELISPOT) assay. The IL-8 expression was assessed immunohistochemically in patients' tumor tissue sections and correlated with the expression of COX-2, VEGF, IL-6, and microvessel morphometry (assessed using CD34 antibody). Eighteen cases were also stained for CD31 and used as an additional vessel marker to validate our results regarding microvessel morphometry. IL-6 and IL-8 were highly secreted in the PBMCs of glioma patients compared with controls (p = 0.0001, p < 0.0001, respectively), with a positive correlation between IL-8 expression and secretion levels (p = 0.001). IL-8 immunoreactivity was detected in malignant cells or macrophages in perivascular areas and in pseudopalisading cells around necrosis and was positively correlated with histological grade (p = 0.0175) and tumor necrosis (p = 0.0793). IL-6 and IL-8 expression levels were positively correlated (p = 0.0036) and associated with COX-2 and VEGF expression (IL-6: p = 0.0133, p = 0.065; IL-8: p = 0.0139, p = 0.0101), but not with microvessel morphometry, by either CD31 or CD34. The coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways. Moreover, our study seems to be the first attempt to link IL-8 expression by tumor cells with histological grade, implicating its potent role in gliomagenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332096     DOI: 10.1016/j.humimm.2009.03.011

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  25 in total

1.  A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

Authors:  Louis B Nabors; John B Fiveash; James M Markert; Manasi S Kekan; George Y Gillespie; Zhi Huang; Martin J Johnson; Sreelatha Meleth; Huichien Kuo; Candece L Gladson; Hassan M Fathallah-Shaykh
Journal:  Arch Neurol       Date:  2010-03

Review 2.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

Review 3.  Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.

Authors:  R E Kast
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  Expression of interleukin-8 receptor CXCR2 and suppressor of cytokine signaling-3 in astrocytic tumors.

Authors:  Penelope Korkolopoulou; Georgia Levidou; Elias A El-Habr; Christos Adamopoulos; Vassilis Samaras; Athanasios Zisakis; Nikolaos Kavantzas; Efstathios Boviatsis; Paraskevi Fragkou; Athanasios G Papavassiliou; Efstratios Patsouris; Christina Piperi
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 5.  ELISpot for measuring human immune responses to vaccines.

Authors:  Meredith Slota; Jong-Baeck Lim; Yushe Dang; Mary L Disis
Journal:  Expert Rev Vaccines       Date:  2011-03       Impact factor: 5.217

6.  Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP.

Authors:  Fadee G Mondalek; Sivapriya Ponnurangam; Janita Govind; Courtney Houchen; Shrikant Anant; Panayotis Pantazis; Rama P Ramanujam
Journal:  J Nanobiotechnology       Date:  2010-07-15       Impact factor: 10.435

Review 7.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.

Authors:  Dimitry A Chistiakov; Vladimir P Chekhonin
Journal:  Tumour Biol       Date:  2014-06-27

Review 8.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

9.  Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche.

Authors:  Michael D Brooks; Rajarshi Sengupta; Steven C Snyder; Joshua B Rubin
Journal:  Curr Pathobiol Rep       Date:  2013-06-01

10.  High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.

Authors:  Christina Piperi; Marios S Themistocleous; George A Papavassiliou; Elena Farmaki; Georgia Levidou; Penelope Korkolopoulou; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  Mol Med       Date:  2009-10-12       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.